Innovating Across Disciplines
Semarion is built on fostering collaboration across disciplines to tackle foundational bottlenecks in drug discovery. We operate at the edge of the physical and life sciences by using microchip industry materials and techniques to transform cell-based research.
Enabling the Science that Discovers Better Medicines
Unlocking better medicines for patients involves the long and arduous process of drug discovery. Semarion is building a technology platform that revolutionizes in vitro research on cell models to help create better medicines, faster.
Tarun drives the innovation of the SemaCyte® technology platform through novel material design and engineering that is embedded across Semarion’s product suite.
His background spans running microchip fabrication processes in industry to developing an advanced nanomagnetic therapy for glioblastoma.
Daniel’s work is focussed on developing key applications for the SemaCyte® platform to accelerate cell biology research and cancer drug discovery.
His previous research activities include DNA replication and the DNA damage response, alongside cancer target identification and validation.
Tom heads Semarion’s microfabrication process development and optimisation with a focus on high yield, scalable manufacturing.
He has worked in both industrial and academic settings on development and fabrication projects for advanced materials.
Paul manages the Board and guides the Executive Team on partnering and business development.
He is Chief Business Officer at Mission Therapeutics. Paul has been involved in several trade sales and has executed over $4.5B worth of outlicensing partnerships including the hepatitis C protease inhibitor, Olysio®.
Karolina is an Investment Manager at Parkwalk Advisors, specialised in Healthcare and Life Sciences.
She has over a decade of experience building life sciences and healthcare companies within the Cambridge Cluster. In 2018 she co-founded and successfully delivered the first life sciences startup accelerator in Cambridge with a portfolio value of over £90m. Karolina completed a PhD in protein folding from the University of Cambridge and carried out a drug development postdoc work at MedImmune/AstraZeneca.
Del is a NED and provides key industry insight on product and application development for the SemaCyte® platform.
Del co-founded Essen Biosciences and spearheaded the commercial development of the Incucyte® platform. He is also a Technology scout at Sartorius, and a NED at Axol Biosciences and ELRIG.
Fabrice sits on Semarion’s Research Commitee and advises on implementaion of the SemaCyte® platform for compound screening.
Fabrice is VP at Evotec amd has 20+ years of experiens with compound screening drug discovery throughput optimisation. He managed screening facilities at Cancer Research Technology, MedImmune, UCB, and ICR.
Jacqui is a Human Resources consultant specialising in providing advice and support to start-up and early stage biotech and high-tech SME’s.
Covering all aspects of Human Resources management, her in-house experience has been gained primarily in pharmaceutical, medical devices and pharma services companies, having held UK, Europe-wide and global roles.
Peter is an Investment Director at Martlet Capital, with a focus on early-stage life science investments.
As a former co-founder and General Partner of SV Health Investors, he brings a career background in institutional life sciences venture capital, combined with university technology commercialisation experience.